| 1. | | Recruiting | Music Therapy to Ease Pain and Emotional Distress in Patients With Hematologic Cancer Who Are Undergoing High-Dose Therapy and Stem Cell Transplantation
Conditions: adult Hodgkin's lymphoma; adult non-Hodgkin's lymphoma; Anxiety Disorder; childhood acute myeloid leukemia and other myeloid malignancies; ... |
| 2. | | Recruiting | Bone Marrow Transplantation in Treating Patients With Multiple Myeloma, Chronic Phase Chronic Myelogenous Leukemia, or Agnogenic Myeloid Metaplasia
Conditions: chronic idiopathic myelofibrosis; Chronic Myelogenous Leukemia; Multiple Myeloma; refractory plasma cell neoplasm |
| 3. | | Recruiting | Bortezomib in Treating Patients With Advanced Cancer and Kidney Dysfunction
Conditions: adult non-Hodgkin's lymphoma; adult solid tumor; Multiple Myeloma; refractory plasma cell neoplasm |
| 4. | | Recruiting | CCI-779 in Treating Patients With Relapsed or Refractory Multiple Myeloma
Conditions: stage I multiple myeloma; stage II multiple myeloma; stage III multiple myeloma; refractory plasma cell neoplasm |
| 5. | | Recruiting | Stem Cell Transplantation in Treating Patients With Previously-Treated Multiple Myeloma
Conditions: stage I multiple myeloma; stage II multiple myeloma; stage III multiple myeloma; refractory plasma cell neoplasm |
| 6. | | Recruiting | Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma
Conditions: refractory plasma cell neoplasm; stage I multiple myeloma; stage II multiple myeloma; stage III multiple myeloma |
| 7. | | Recruiting | Bevacizumab With or Without Thalidomide in Treating Patients With Relapsed or Refractory Multiple Myeloma
Conditions: refractory plasma cell neoplasm; stage I multiple myeloma; stage II multiple myeloma; stage III multiple myeloma |
| 8. | | Recruiting | Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma
Conditions: refractory plasma cell neoplasm; stage I multiple myeloma; stage II multiple myeloma; stage III multiple myeloma |
| 9. | | Recruiting | Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients Who Have Multiple Myeloma or Primary Systemic Amyloidosis
Conditions: refractory plasma cell neoplasm; stage I multiple myeloma; stage II multiple myeloma; stage III multiple myeloma; primary systemic amyloidosis |
| 10. | | Recruiting | O6-benzylguanine And Carmustine in Treating Patients With Multiple Myeloma
Conditions: refractory plasma cell neoplasm; stage I multiple myeloma; stage II multiple myeloma; stage III multiple myeloma |
| 11. | | Recruiting | Antineoplaston Therapy in Treating Patients With Multiple Myeloma
Conditions: refractory plasma cell neoplasm; stage I multiple myeloma; stage II multiple myeloma; stage III multiple myeloma |
| 12. | | Recruiting | High-Dose Melphalan Followed by Peripheral Stem Cell Transplantation in Treating Patients With Amyloidosis
Conditions: refractory plasma cell neoplasm; stage I multiple myeloma; stage II multiple myeloma; stage III multiple myeloma; primary systemic amyloidosis |
| 13. | | Recruiting | Bortezomib and Liposomal Doxorubicin in Treating Patients With Multiple Myeloma
Conditions: stage I multiple myeloma; stage II multiple myeloma; stage III multiple myeloma |
| 14. | | Not yet recruiting | Melphalan and Amifostine Followed By Stem Cell Transplantation in Treating Patients With Multiple Myeloma
Conditions: Drug Toxicity; stage I multiple myeloma; stage II multiple myeloma; stage III multiple myeloma |
| 15. | | Not yet recruiting | Dexamethasone With or Without CC-5013 in Treating Patients With Newly Diagnosed Multiple Myeloma
Conditions: stage I multiple myeloma; stage II multiple myeloma; stage III multiple myeloma |
| 16. | | Recruiting | Thalidomide and Prednisone After Autologous Stem Cell Transplantation in Treating Patients With Multiple Myeloma
Conditions: stage I multiple myeloma; stage II multiple myeloma; stage III multiple myeloma |
| 17. | | Recruiting | Thalidomide, Chemotherapy, and Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma
Conditions: stage I multiple myeloma; stage II multiple myeloma; stage III multiple myeloma |
| 18. | | Recruiting | Combination Chemotherapy, Peripheral Stem Cell Transplantation, Biological Therapy, Pamidronate and Thalidomide in Treating Patients With Multiple Myeloma
Conditions: stage I multiple myeloma; stage II multiple myeloma; stage III multiple myeloma |
| 19. | | Recruiting | Antibiotic Therapy in Preventing Early Infection in Patients With Multiple Myeloma Who Are Receiving Chemotherapy
Conditions: stage I multiple myeloma; stage II multiple myeloma; stage III multiple myeloma; Infection |
| 20. | | Recruiting | Melphalan, Arsenic Trioxide, and Ascorbic Acid in Treating Patients With Relapsed or Refractory Multiple Myeloma
Conditions: stage II multiple myeloma; stage III multiple myeloma; refractory plasma cell neoplasm |
| 21. | | Recruiting | Tandem Autologous Stem Cell Transplantation With or Without Maintenance Therapy After the Second Transplantation Compared With Autologous Stem Cell Transplantation Followed By Matched Sibling Allogeneic Stem Cell Transplantation in Patients With Stage II or Stage III Multiple Myeloma
Conditions: stage II multiple myeloma; stage III multiple myeloma; refractory plasma cell neoplasm |
| 22. | | Recruiting | FR901228 in Treating Patients With Relapsed or Refractory Multiple Myeloma
Conditions: stage II multiple myeloma; stage III multiple myeloma; refractory plasma cell neoplasm |
| 23. | | Recruiting | Chemotherapy, Stem Cell Transplantation and Donor and Patient Vaccination for Treatment of Multiple Myeloma
Condition: Multiple Myeloma |
| 24. | | Recruiting | Study Comparing Skeletal Targeted Radiotherapy (STR) plus Melphalan to Melphalan Alone, with Stem Cell Transplant in Multiple Myeloma
Condition: Multiple Myeloma |
| 25. | | Recruiting | Study of Combination Thalidomide Plus Glucocorticoid Therapy Versus Glucocorticoid Therapy Alone as Induction Therapy for Previously Untreated Subjects with Multiple Myeloma
Condition: Multiple Myeloma |
| 26. | | Recruiting | A Study of PS-341 Given to Patients With Multiple Myeloma who Experienced Progressive Disease After Receiving Dexamethasone in M34101-039
Condition: Multiple Myeloma |
| 27. | | Recruiting | Study of Oral SCIO-469 in Relapsed, Refractory Patients with Multiple Myeloma
Condition: Multiple Myeloma |
| 28. | | Recruiting | Combination Bisphosphonate and Anti-Angiogenesis Therapy with Pamidronate and Thalidomide
Condition: Multiple Myeloma |
| 29. | | Recruiting | Combination Bisphosphonate and Anti-Angiogenesis Therapy with Pamidronate and Thalidomide
Condition: Multiple Myeloma |
| 30. | | Recruiting | Adjuvant Bortezomib Maintenance Therapy After Autologous Peripheral Stem Cell Transplantation in Treating Patients With Intermediate or Advanced Multiple Myeloma
Conditions: stage II multiple myeloma; stage III multiple myeloma |
| 31. | | Recruiting | High-Dose Melphalan and Autologous Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma or Primary Systemic Amyloidosis
Conditions: primary systemic amyloidosis; stage II multiple myeloma; stage III multiple myeloma |
| 32. | | Recruiting | Combination Chemotherapy With or Without Thalidomide in Treating Patients With Multiple Myeloma
Conditions: stage II multiple myeloma; stage III multiple myeloma |
| 33. | | Recruiting | Combination Chemotherapy in Treating Patients With Stage II or Stage III Multiple Myeloma
Conditions: stage II multiple myeloma; stage III multiple myeloma |
| 34. | | Recruiting | Safety and Efficacy of Atiprimod for Patients with Refractory Multiple Myeloma
Condition: Multiple Myeloma |
| 35. | | Recruiting | Study of Tumor Antigen-Pulsed Autologous Dendritic Cell Vaccination Administrated Subcutaneously or Intranodally
Condition: Multiple Myeloma |
| 36. | | Recruiting | Study of Combination PS-341 and Thalidomide in Multiple Myeloma
Condition: Multiple Myeloma |
| 37. | | Recruiting | Repeat-Dose Pharmacokinetics and Pharmacodynamics of Bortezomib in Patients with Relapsed Multiple Myeloma
Condition: Multiple Myeloma |
| 38. | | Recruiting | Xcellerated T CellsTM in Patients with Multiple Myeloma
Condition: Multiple Myeloma |
| 39. | | Recruiting | Combined Bone Marrow and Kidney Transplant for Multiple Myeloma with Kidney Failure
Conditions: Kidney Failure, Chronic; Multiple Myeloma |
| 40. | | Recruiting | Specialized Blood Cell Transplants for Cancers of the Blood and Bone Marrow
Conditions: Hematologic Disease; Lymphoma; Multiple Myeloma; Myelodysplastic Syndrome; Myeloproliferative Disorder |
| 41. | | Recruiting | 2-Methoxyestradiol in Treating Patients With Advanced Solid Tumors
Conditions: refractory plasma cell neoplasm; stage III multiple myeloma; unspecified adult solid tumor, protocol specific |
| 42. | | Recruiting | Study of Bortezomib and Revlimid™ for Patients Relapsing or Progressing on Total Therapy II
Condition: Multiple Myeloma |
| 43. | | Not yet recruiting | Study of MAGE-A3 and NY-ESO-1 Immunotherapy in Combination with DTPACE Chemotherapy and Autologous Transplantation in Multiple Myeloma
Condition: Multiple Myeloma |
| 44. | | Recruiting | Study of KIR-Ligand Mismatched Haplo-Identical Natural Killer Cells Transfused Before Autologous Stem Cell Transplant
Condition: Multiple Myeloma |
| 45. | | Recruiting | A Phase I Study of DVd +/ CC-5013 in Relapsed Refractory Multiple Myeloma (MM)
Condition: Multiple Myeloma |
| 46. | | Recruiting | UARK 2003-33, Total Therapy III
Condition: Multiple Myeloma |
| 47. | | Recruiting | Study of SGN-40 (anti-huCD40 mAb) in Patients with Refractory or Recurrent Multiple Myeloma
Condition: Multiple Myeloma |
| 48. | | Recruiting | Pegfilgrastim (Neulasta) for Stem Cell Mobilization in Patients with Multiple Myeloma
Condition: Multiple Myeloma |
| 49. | | Recruiting | Double Cord Blood Transplant Study
Conditions: Leukemia, Lymphocytic, Acute; Leukemia, Myelocytic, Acute; Leukemia, Myeloid, Chronic; Lymphoma, Non-Hodgkin; Multiple Myeloma |
| 50. | | Recruiting | Safety Study of AP23573 in Patients with Advanced, Refractory or Recurrent Malignancies
Conditions: Tumors; Lymphoma; Multiple Myeloma |
